IOL Chemicals and Pharmaceuticals Limited

IOLCP Declares ₹1 Interim Dividend; Q3 FY26 Results Announced

IOL Chemicals and Pharmaceuticals Limited announced its Q3 FY26 results with total income at ₹585.68 crore and net profit after tax at ₹20.58 crore. For the nine months ended Dec 31, 2025, income was ₹1719.15 crore and net profit after tax was ₹84.54 crore. The company declared an interim dividend of ₹1 per share, with a record date of February 17, 2026.

IOLCP Q3 & 9M FY26: Revenue ₹580.4 Cr, PBT ₹38.8 Cr, EBITDA ₹62.6 Cr

IOL Chemicals and Pharmaceuticals Limited reported Q3 FY26 standalone revenue of ₹580.4 crore, up 10.9% YoY. PBT increased by 39.3% to ₹38.8 crore, and EBITDA grew 22.8% to ₹62.6 crore. For 9M FY26, revenue was ₹1,699.6 crore, with PBT at ₹124.8 crore and EBITDA at ₹196.1 crore.

IOLCP Q3 FY26 PBT Up 39% YoY to ₹38.8 Cr on 10.9% Revenue Growth

IOL Chemicals and Pharmaceuticals Limited reported Q3 FY26 standalone revenue of ₹580.4 crore, up 10.9% YoY. PBT surged 39.3% to ₹38.8 crore, with margins expanding. The Pharmaceuticals segment revenue grew 18% YoY, contributing 61% to total revenue. The company aims to expand in regulated markets and enhance R&D.

IOLCP Declares Interim Dividend of ₹1/Share, Sets Record Date for Feb 17

IOL Chemicals and Pharmaceuticals Limited announced its Q3 FY26 results. The company declared an interim dividend of ₹1 per share. The record date for the dividend is February 17, 2026. The financial results for the quarter and nine months ended December 31, 2025, were approved.

IOLCP Declares Interim Dividend of ₹1/Share; Q3 FY26 Results Approved

IOL Chemicals and Pharmaceuticals Limited announced its Q3 FY26 results, declaring an interim dividend of ₹1 per share. The record date for the dividend is February 17, 2026. The company also reported an exceptional item of ₹11.21 crore related to new labor codes.

IOL Chemicals to Host Analyst Call on Feb 12 for Q3 & 9M FY26 Results

IOL Chemicals and Pharmaceuticals Limited will hold an analyst/investor conference call on February 12, 2026, at 3:00 PM IST. The call will discuss the company's financial performance for Q3 and 9M FY26, ending December 31, 2025. Key management will participate in the discussion.

IOLCP Subsidiary IOL Life Sciences Applies for Striking Off Name

IOLCP's wholly owned subsidiary, IOL Life Sciences Limited, has applied to the Registrar of Companies to strike off its name. The subsidiary had zero revenue and a net worth of ₹638,838 as of March 31, 2025. The application is subject to regulatory approvals.

IOL Chemicals & Pharmaceuticals Files SEBI Compliance Certificate for Q3 FY26

IOL Chemicals and Pharmaceuticals Limited has filed a certificate under SEBI (Depositories and Participants) Regulations, 2018. This compliance filing is for the quarter ended December 31, 2025, and confirms the processing of physical share certificates for dematerialization.

IOL Chemicals Trading Window Closed Jan 1 to Post Q3 Results

IOL Chemicals and Pharmaceuticals Limited will close its trading window from January 1, 2026. The window will reopen 48 hours after the declaration of unaudited financial results for the quarter and nine months ended December 31, 2025. The board meeting date for results approval will be announced later.

EDQM grants CEP Certificate for IOLCP's Minoxidil

IOLCP Receives EDQM Certificate for MINOXIDIL API, used for hair loss treatment, on December 4, 2025.

IOLCP: Newspaper Publication for Physical Share Re-lodgement

IOLCP announced a newspaper publication regarding a special window for re-lodgement of transfer requests for physical shares from 7 May 2025 to 6 December 2025. Dematerialization is required.

IOLCP Announces Transcript of Earnings Conference Call for Q2 & H1 FY'26

IOLCP released the transcript of its earnings conference call held on 13th November 2025, following the declaration of financial results for the quarter and half year ended 30th September 2025.

IOLCP releases audio recording of Analysts/Investors Call for Q2 & H1 FY26 financial results

IOLCP released the audio recording of its Analysts/Investors Call for Q2 & H1 FY26 financial results, held on November 13, 2025, providing insights into the company's performance.

IOLCP Announces Investor Presentation for Q2 & H1 FY26

IOLCP announces investor presentation for Q2 & H1 FY26, reports standalone revenue of ₹ 567.5 crore for Q2 & ₹ 1,119.2 crore for H1. It received CEP certification & incorporated a UK subsidiary.

IOL Chemicals and Pharmaceuticals publishes unaudited Q2 and H1 FY26 financial results

IOLCP published unaudited standalone and consolidated financial results for Q2 and H1 FY26. Income rose YoY, but net profit and EPS declined YoY, showing mixed performance.

IOL Chemicals Reports Strong Q2 & H1 FY26 Results with Margin Expansion

IOL Chemicals & Pharma announced Q2 & H1 FY26 results with revenue up 7.9% & 8.9% YOY respectively. EBITDA increased by 33.3% & 25.7% YOY respectively. They also incorporated IOL Pharmaxis UK Limited.

IOLCP Approves Un-Audited Financial Results for Quarter and Half Year Ended 30 Sept 2025

IOLCP approves un-audited financial results for the quarter and half year ended 30 Sept 2025. Standalone total income for the quarter stood at ₹574.41 crore and PAT at ₹30.00 crore.

IOLCP Announces Analyst/Investor Conference Call for Q2 & H1 FY26

IOLCP is organizing a conference call on 13 November 2025 to discuss the financial performance for the second quarter and half year ended 30 September 2025.

IOLCP receives EDQM CEP for Sitagliptin Phosphate Monohydrate

IOL Chemicals and Pharmaceuticals Limited received a Certificate of Suitability (CEP) from EDQM for its API product "Sitagliptin Phosphate Monohydrate" on 27th October 2025, enabling market access.

IOL Chemicals incorporates wholly-owned subsidiary IOL Pharmaxis UK Limited

IOL Chemicals and Pharmaceuticals Limited incorporated IOL Pharmaxis UK Limited as a wholly-owned subsidiary in the UK on October 16, 2025, with GBP 10,000 share capital, for pharmaceutical/chemical business.

EDQM issues CEP Certificate for Pantoprazole Sodium Sesquihydrate

IOLCP receives CEP certificate from EDQM for its API product Pantoprazole Sodium Sesquihydrate Process -III, used in drugs for treating GERD and other conditions.

IOLCP: Reminder to Shareholders to Update KYC

IOLCP Clarifies Q1 FY26 Financial Results Format and Standalone-Consolidated Figures to NSE

IOLCP to hold virtual meetings with Institutional Investors/Analysts on 15 Sep 2025

IOLCP Launches 'Saksham Niveshak' Campaign to Update Shareholder KYC & Prevent Dividend Transfer to IEPF

IOLCP: Summary of Proceedings of 38th Annual General Meeting

IOLCP approves Q1FY26 results, UK subsidiary formation, Minoxidil project.

IOL Chemicals to Hold 38th AGM on August 22, 2025; Key Resolutions Include Director Re-appointments and Remuneration